The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients
Open accessAbstract
BACKGROUND: Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. We undertook an individual patient data meta-analysis to assess the impact on outcomes of the type, number, and duration of drugs used to treat MDR-TB. METHODS AND FINDINGS: Three recent systematic reviews were used to identify studies reporting treatment outcomes of microbiologically confirmed MDR-TB. Study authors were contacted to solicit individual patient data including clinical characteristics, treatment given, and outcomes. Random effects multivariable logistic meta-regression was used to estimate adjusted odds of treatment success. Adequate treatment and outcome data were provided for 9,153 patients with MDR-TB from 32 observational studies. Treatment success, compared to failure/relapse, was associated with use of: later generation quinolones, (adjusted odds ratio [aOR]: 2.5 [95% CI 1.1-6.0]), ofloxacin (aOR: 2.5 [1.6-3.9]), ethionamide or prothionamide (aOR: 1.7 [1.3-2.3]), use of four or more likely effective drugs in the initial intensive phase (aOR: 2.3 [1.3-3.9]), and three or more likely effective drugs in the continuation phase (aOR: 2.7 [1.7-4.1]). Similar results were seen for the association of treatment success compared to failure/relapse or death: later generation quinolones, (aOR: 2.7 [1.7-4.3]), ofloxacin (aOR: 2.3 [1.3-3.8]), ethionamide or prothionamide (aOR: 1.7 [1.4-2.1]), use of four or more likely effective drugs in the initial intensive phase (aOR: 2.7 [1.9-3.9]), and three or more likely effective drugs in the continuation phase (aOR: 4.5 [3.4-6.0]). CONCLUSIONS: In this individual patient data meta-analysis of observational data, improved MDR-TB treatment success and survival were associated with use of certain fluoroquinolones, ethionamide, or prothionamide, and greater total number of effective drugs. However, randomized trials are urgently needed to optimize MDR-TB treatment. Please see later in the article for the Editors' Summary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Cited by
Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis
Seung, K. J., Keshavjee, S., & Rich, M. L. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017863 · Cited by 805
Self-citationMultidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline
Diacon, A. H., Pym, A., Grobusch, M. P., de los Rios, J. M., Gotuzzo, E., Vasilyeva, I., Leimane, V., Andries, K., Bakare, N., De Marez, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313865 · Cited by 746
Self-citationAhmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J.-W. C., Anderson, L. F., Baghaei, P., Bang, D., Barry, P. M., Bastos, M. L., Behera, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31644-1 · Cited by 632
Self-citationWorld Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
Falzon, D., Schünemann, H. J., Harausz, E., González-Angulo, L., Lienhardt, C., Jaramillo, E., & Weyer, K. (2017) · European Respiratory Journal · doi:10.1183/13993003.02308-2016 · Cited by 420
Self-citationBuilding a tuberculosis-free world: The Lancet Commission on tuberculosis
Reid, M. J. A., Arinaminpathy, N., Bloom, A., Bloom, B. R., Boehme, C., Chaisson, R., Chin, D. P., Churchyard, G., Cox, H., Ditiu, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30024-8 · Cited by 361
Self-citation
Metadata
- Authors
- Ahuja, S. D., Ashkin, D., Avendano, M., Banerjee, R., Bauer, M., Bayona, J. N., Becerra, M. C., Benedetti, A., Burgos, M., Centis, R., Chan, E. D., Chiang, C.-Y., Cox, H., D'Ambrosio, L., DeRiemer, K., Dung, N. H., Enarson, D., Falzon, D., Flanagan, K., Flood, J., Garcia-Garcia, M. L., Gandhi, N., Granich, R. M., Hollm-Delgado, M. G., Holtz, T. H., Iseman, M. D., Jarlsberg, L. G., Keshavjee, S., Kim, H.-R., Koh, W.-J., Lancaster, J., Lange, C., de Lange, W. C. M., Leimane, V., Leung, C. C., Li, J., Menzies, D., Migliori, G. B., Mishustin, S. P., Mitnick, C. D., Narita, M., O'Riordan, P., Pai, M., Palmero, D., Park, S.-K., Pasvol, G., Peña, J., Pérez-Guzmán, C., Quelapio, M. I. D., Ponce-de-Leon, A., Riekstina, V., Robert, J., Royce, S., Schaaf, H. S., Seung, K. J., Shah, L., Shim, T. S., Shin, S. S., Shiraishi, Y., Sifuentes-Osornio, J., Sotgiu, G., Strand, M. J., Tabarsi, P., Tupasi, T. E., van Altena, R., Van der Walt, M., Van der Werf, T. S., Vargas, M. H., Viiklepp, P., Westenhouse, J., Yew, W. W., Yim, J.-J., & Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-08-28
- Volume
- 9
- Issue
- 8
- Pages
- e1001300
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2168509294
- Cited by
- 535
- References
- 1
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. https://app.cochat.ai/papers/10.1371/journal.pmed.1001300
- The paper
- Ahuja, S. D., Ashkin, D., Avendano, M., Banerjee, R., Bauer, M., Bayona, J. N., Becerra, M. C., Benedetti, A., Burgos, M., Centis, R., Chan, E. D., Chiang, C.-Y., Cox, H., D'Ambrosio, L., DeRiemer, K., Dung, N. H., Enarson, D., Falzon, D., Flanagan, K., . . . Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. (2012). Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Medicine. https://doi.org/10.1371/journal.pmed.1001300
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
